The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 25, 2023

Filed:

Jun. 10, 2022
Applicant:

The Scripps Research Institute, La Jolla, CA (US);

Inventors:

Arnab K. Chatterjee, San Diego, CA (US);

Jian Jeffrey Chen, San Diego, CA (US);

Elshan Nakath, La Jolla, CA (US);

Alireza Rahimi, La Jolla, CA (US);

Anil Kumar Gupta, San Diego, CA (US);

Gennadii Grabovyi, La Jolla, CA (US);

Katy Wilson, La Jolla, CA (US);

Sourav Ghorai, La Jolla, CA (US);

Armen Nazarian, La Jolla, CA (US);

James Pedroarena, La Jolla, CA (US);

Wrickban Mazumdar, La Jolla, CA (US);

Frank Weiss, La Jolla, CA (US);

Lirui Song, San Diego, CA (US);

Malina A. Bakowski, La Jolla, CA (US);

Laura Riva, San Diego, CA (US);

Karen Wolff, Encinitas, CA (US);

Case W. McNamara, San Marcos, CA (US);

Thomas F. Rogers, Del Mar, CA (US);

Jacqueline Malvin, San Diego, CA (US);

Shuangwei Li, San Diego, CA (US);

Sean Joseph, San Diego, CA (US);

Ashley Woods, San Diego, CA (US);

Yuyin Liu, San Diego, CA (US);

Neechi Okwor, Del Mar, CA (US);

Assignee:

The Scripps Research Institute, La Jolla, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/12 (2006.01); A61K 38/55 (2006.01); C07D 207/267 (2006.01); C07D 211/76 (2006.01); C07D 403/12 (2006.01); C07D 405/10 (2006.01); C07D 405/12 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); C07D 493/04 (2006.01);
U.S. Cl.
CPC ...
C07D 401/12 (2013.01); A61K 38/55 (2013.01); C07D 207/267 (2013.01); C07D 211/76 (2013.01); C07D 403/12 (2013.01); C07D 405/10 (2013.01); C07D 405/12 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 493/04 (2013.01);
Abstract

Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: wherein R, R, R, R, R, R, and A are defined in the present disclosure. The compounds are potent inhibitors of the main protease (M) of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), and they are useful in treating or preventing COVID-19 in a subject.


Find Patent Forward Citations

Loading…